Compound class:
Peptide or derivative
Comment: Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5]. |
| Immunopharmacology Comments |
| Blisibimod is a clinical candidate in the search for effective therapy for systemic lupus erythematosus (SLE) [3-4,6-7] and other autoimmune diseases. Preliminary results from the Phase 3 CHABLIS-SC1 study (NCT01395745) showed some improvement relative to placebo, but this did not reach statistical significance (results yet to be published in a peer reviewed article). |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Blisibimod is an investigational SLE agent. | 2 |
